Autopsy report · NCT02638909

Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.

“Lack of Enrollment”

The sponsor’s own words in the registry.

Life of this trial

Ran for about 2 years 3 months before it stopped.
4 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: Criterium, Inc.
Sponsor type: Industry
Conditions: Colorectal Adenocarcinoma; Cholangiocarcinoma; Pancreatic Adenocarcinoma; Hepatocellular Adenocarcinoma; Gastric Adenocarcinoma; Esophageal Adenocarcinoma
Interventions: ceritinib
Participants: 4
Sites: 6
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.